dapagliflozin + evogliptin + metformin

This drug is a **fixed-dose combination** of three oral antihyperglycemic agents: dapagliflozin, evogliptin, and metformin, used for the management of type 2 diabetes mellitus. - **Dapagliflozin** is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that lowers blood glucose by increasing urinary glucose excretion. - **Evogliptin** is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin (GLP-1 and GIP) levels, leading to increased insulin release and decreased glucagon secretion in a glucose-dependent manner. - **Metformin** is a biguanide that reduces hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity. The combination provides complementary mechanisms to improve glycemic control in patients with type 2 diabetes. This triple combination is intended for patients insufficiently controlled with two of the agents or in whom initial combination therapy is appropriate. As of now, dapagliflozin + evogliptin + metformin has regulatory approval and marketed use primarily in South Korea and limited Asian markets.